Moleculin Biotech Files 8-K with Corporate Updates

TL;DR

Moleculin Biotech filed an 8-K on Aug 27th for an Aug 21st event, updating bylaws and fiscal year.

AI Summary

Moleculin Biotech, Inc. filed an 8-K on August 27, 2025, reporting an event on August 21, 2025. The filing indicates amendments to its Articles of Incorporation or Bylaws, a change in its fiscal year, and includes Regulation FD Disclosure and Financial Statements and Exhibits. The company is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This filing signals potential changes in Moleculin Biotech's corporate structure or reporting periods, which could impact how investors interpret their financial performance and strategic direction.

Risk Assessment

Risk Level: low — The filing is procedural and relates to corporate governance and reporting, not a direct financial event or material adverse change.

Key Players & Entities

• Moleculin Biotech, Inc. (company) — Registrant
• August 21, 2025 (date) — Date of earliest event reported
• August 27, 2025 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• December 31 (date) — Fiscal year end

FAQ

Filing Documents

• mbrx20250826_8k.htm (8-K) — 28KB
• ex_857436.htm (EX-3.1) — 12KB
• ex_857342.htm (EX-99.1) — 21KB
• a01.jpg (GRAPHIC) — 10KB
• 0001437749-25-027798.txt ( ) — 234KB
• mbrx-20250821.xsd (EX-101.SCH) — 3KB
• mbrx-20250821_def.xml (EX-101.DEF) — 12KB
• mbrx-20250821_lab.xml (EX-101.LAB) — 16KB
• mbrx-20250821_pre.xml (EX-101.PRE) — 12KB
• mbrx20250826_8k_htm.xml (XML) — 3KB

03

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Chang in Fiscal Year As previously disclosed, at the Moleculin Biotech, Inc. (the "Company") annual meeting of stockholders held on August 18, 2025, the Company's stockholders approved, among other matters, a proposal to approve a Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation (the "Certificate Amendment") which would amend the Company's existing certificate of incorporation, as amended, to increase the number of authorized shares of the Company's common stock from 100,000,000 shares to 500,000,000 shares. The Certificate Amendment became effective upon filing with the Delaware Secretary of State on August 21, 2025. A copy of the Certificate Amendment is filed as Exhibit 3.1 hereto and is incorporated in this Item 5.03 by reference.

01

Item 7.01 Regulation FD Disclosure On August 27, 2025, Moleculin Biotech, Inc. (the "Company"), issued a press release which announced the completion of its Phase 1B/2 (MB-106) clinical trial evaluating Annamycin in combination with Cytarabine (also known as "Ara-C" and for which the combination of Annamycin and Ara-C is referred to as AnnAraC) for the treatment of subjects with acute myeloid leukemia (AML). A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended ("Securities Act"), unless specifically identified therein as being incorporated by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Amendment to Amended and Restated Certificate of Incorporation of Moleculin Biotech, Inc., dated August 21, 2025 99.1 Press Release dated August 27, 2025 104 Cover page Interactive Data File (formatted as Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MOLECULIN BIOTECH, INC. Date: August 27, 2025 By: /s/ Jonathan P. Foster Jonathan P. Foster

View Full Filing

View this 8-K filing on SEC EDGAR